424B4 Prospectus: Black Hawk SPAC Merger Values Vesicor at $70M

Key takeaways

• Black Hawk Acquisition Corporation filed a 424B4 proxy statement/prospectus for its merger with Vesicor Therapeutics, Inc., with a shareholder meeting set for October 13, 2026.
• Vesicor’s equity value is set at $70,000,000. Consideration to Vesicor holders is that amount divided by the per-share redemption price of Black Hawk’s Class A shares.
• Earlier redemptions left about $22.7 million in the trust account, and the business combination agreement has no minimum cash condition.
• The combined company will be renamed Vesicor Therapeutics Holdings, Inc. and plans to stay on Nasdaq under a new ticker.

What this 424B4 prospectus covers

This 424B4 is not an IPO prospectus. It is the final proxy statement/prospectus for a de-SPAC transaction, in which a blank-check company merges with an operating business and becomes its public vehicle. Reading a 424B4 prospectus in this setting means looking at deal terms, trust cash and valuation rather than an offering price.

Under a business combination agreement signed on April 26, 2025, Black Hawk will first domesticate from the Cayman Islands to Delaware. A Black Hawk subsidiary, BH Merger Sub, will then merge into Vesicor, which survives as a wholly owned subsidiary. Black Hawk shareholders will vote at an extraordinary general meeting on October 13, 2026, at the company’s office in Danville, California, and by webcast.

How the $70 million valuation was set

The equity value of $70,000,000 came from Vesicor’s management, which the proxy says presented a comparable market analysis in February 2025. It drew on a U.S. Department of Health and Human Services scenario tree for pre-clinical therapeutic development, private biotech valuation benchmarks from Bay Bridge Bio, and public financing data for pre-clinical companies in adjacent areas. Black Hawk’s board also obtained a fairness opinion from ERShares, which concluded that the consideration was fair, from a financial point of view, to Black Hawk and its shareholders.

Because the share count issued depends on the redemption price, the valuation is fixed in dollars rather than shares. The aggregate merger consideration equals $70,000,000 divided by the price at which each Black Hawk Class A share can be redeemed.

Item	Detail
Equity value of Vesicor	$70,000,000
Shares redeemed July 2025	4,775,923 (about 69.2%)
Paid out at redemption	About $51.0 million, near $10.68 a share
Public shares remaining	2,124,077
Trust balance after redemptions	About $22.7 million

Trust cash and extension funding

Black Hawk has already lost most of its trust to redemptions. At an extension meeting on July 8, 2025, holders of 4,775,923 public shares redeemed. Black Hawk can extend its deadline month by month through December 22, 2026, up to 18 times, by depositing $150,000 into the trust each time. The sponsor and Vesicor fund those deposits jointly, and Black Hawk’s portion is financed through unsecured convertible notes to the sponsor of up to $1,600,000 in aggregate, convertible at $1.00 a share. The notes carry interest of 6% a year for the first and 10% for later ones. The proxy says the parties agreed to proceed without a minimum cash condition, since Black Hawk could not guarantee that investors would leave money in the trust, and a break-up fee was written into the deal to hold both sides to it. If the deal does not close, Black Hawk may not find another candidate before its deadline and would have to liquidate.

The target

Vesicor is an early development stage biopharmaceutical company with no significant operating revenue. Its sole product candidate, ecm-RV/p53, is pre-clinical, and the proxy says it is potentially two or more years from regulatory approval. Closing conditions include an effective registration statement and conditional Nasdaq approval.

What it means for IPO watchers

Compared with a traditional IPO, a de-SPAC prospectus shows how little price discovery may occur when trust cash has shrunk and the valuation comes from a negotiated comparables exercise. The vote on October 13 and the redemption level that follows will determine how much cash reaches Vesicor.